Anti-Hypertensive Drugs - Papua New Guinea

Papua New Guinea

The revenue in Papua New Guinea's Anti-Hypertensive Drugs market is anticipated to rise to US$1.14m in 2024.
It is expected that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of -0.89%, leading to a market volume of US$1.09m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$12,290.00m in 2024.
Papua New Guinea's anti-hypertensive drug market is witnessing a surge in demand due to the country's high prevalence of hypertension and growing awareness about the importance of managing the condition.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Papua New Guinea has been steadily growing in recent years.

Customer preferences: As in many other countries, the aging population of Papua New Guinea is driving demand for anti-hypertensive drugs. Additionally, the increasing prevalence of hypertension in the country has led to a greater demand for these medications.

Trends in the market: One trend in the Anti-Hypertensive Drugs market in Papua New Guinea is the increasing availability of generic versions of these medications. This has led to greater affordability and accessibility for patients. Another trend is the growing importance of combination therapies, which allow patients to take multiple medications in one pill.

Local special circumstances: Papua New Guinea is a developing country with limited healthcare infrastructure. This can make it difficult for patients to access the medications they need. Additionally, cultural beliefs and traditional medicine practices can sometimes lead patients to avoid taking Western medications.

Underlying macroeconomic factors: The economy of Papua New Guinea is heavily reliant on natural resources, particularly mining and oil. This can lead to fluctuations in the country's economic growth and can impact the ability of patients to afford medications. Additionally, the country has a high burden of infectious diseases, which can divert resources away from chronic disease management.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.